GR-pKa: a message-passing neural network with retention mechanism for pKa prediction.

Journal: Briefings in bioinformatics
Published Date:

Abstract

During the drug discovery and design process, the acid-base dissociation constant (pKa) of a molecule is critically emphasized due to its crucial role in influencing the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties and biological activity. However, the experimental determination of pKa values is often laborious and complex. Moreover, existing prediction methods exhibit limitations in both the quantity and quality of the training data, as well as in their capacity to handle the complex structural and physicochemical properties of compounds, consequently impeding accuracy and generalization. Therefore, developing a method that can quickly and accurately predict molecular pKa values will to some extent help the structural modification of molecules, and thus assist the development process of new drugs. In this study, we developed a cutting-edge pKa prediction model named GR-pKa (Graph Retention pKa), leveraging a message-passing neural network and employing a multi-fidelity learning strategy to accurately predict molecular pKa values. The GR-pKa model incorporates five quantum mechanical properties related to molecular thermodynamics and dynamics as key features to characterize molecules. Notably, we originally introduced the novel retention mechanism into the message-passing phase, which significantly improves the model's ability to capture and update molecular information. Our GR-pKa model outperforms several state-of-the-art models in predicting macro-pKa values, achieving impressive results with a low mean absolute error of 0.490 and root mean square error of 0.588, and a high R2 of 0.937 on the SAMPL7 dataset.

Authors

  • Runyu Miao
    Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Danlin Liu
    Innovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, No. 3663, Zhongshan North Road, Putuo District, Shanghai, 200062, China.
  • Liyun Mao
    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, No. 130, Meilong Road, Xuhui District, Shanghai, 200237, China.
  • Xingyu Chen
    Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China.
  • Leihao Zhang
    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, No. 130, Meilong Road, Xuhui District, Shanghai, 200237, China.
  • Zhen Yuan
    Bioimaging Core, Faculty of Health Sciences, University of Macau, Macau SAR, China.
  • Shanshan Shi
    CICU, Children's Hospital, Zhejiang University School of Medicine, 310052 Hangzhou, Zhejiang, China.
  • Honglin Li
    Innovation Center for AI and Drug Discovery, East China Normal University, China.
  • Shiliang Li
    Innovation Center for AI and Drug Discovery, East China Normal University, China.